![]() | |
Clinical data | |
---|---|
Other names | TA-8995; AMG-899 |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C32H31F9N4O5 |
Molar mass | 722.609 g·mol−1 |
3D model (JSmol) | |
| |
|
Obicetrapib is an experimental CETP inhibitor that is intended to treat dyslipidemia. In a clinical trial, as an add-on to statins, it decreased "LDL-C concentration (by up to 51%; P < 0.0001), the primary trial outcome. As compared with placebo, obicetrapib treatment also significantly (P < 0.0001) decreased apolipoprotein B (by up to 30%) and non-high-density lipoprotein cholesterol (non-HDL-C) concentration (by up to 44%), and significantly (P < 0.0001) increased HDL-C concentration (by up to 165%; the secondary trial outcomes)".[1][2] As of 2023, it is in a Phase III trial.[3]